We were proud to take part in the 23rd HealthWorld event by AmCham Greece, where we highlighted the importance of value-based healthcare. The discussion emphasized that optimizing the Clinical Outcomes and the Direct & Indirect Costs ratio is crucial for the sustainability of the healthcare systems.
The session focused on illustrating how the future of healthcare depends on optimizing the balance between clinical outcomes and the direct and indirect costs of care. Value, as emphasized, is not an abstract concept but a measurable reality that manifests over time when the appropriate metrics are applied.
“Value-based healthcare is the future, but it requires a commitment to measuring what truly matters: clinical outcomes and the impact on overall healthcare costs over sufficient time. At SOFMEDICA, we believe that what gets measured, gets done, and we are dedicated to making this a reality for the benefit of patients and healthcare providers alike.” – Evangelos P. Kalamakis, Managing Director, SOFMEDICA.
We have embedded the “Quantify the Impact” principle into our operations, enabling us to rigorously and scientifically evaluate the clinical and financial benefits against a baseline prior to our involvement. This ensures that the value we deliver to healthcare systems is supported by solid, evidence-based data rather than theoretical assumptions.
A key message we conveyed during the discussion was the pivotal role that procurement authorities play in driving this value-based transformation. By incorporating value-related criteria into tender processes, procurement authorities can hold suppliers accountable for delivering measurable outcomes, ensuring that capital investments are aligned with quantified long-term clinical and financial benefits. This is a shift that can elevate healthcare across the board, ensuring better care for patients while maintaining economic sustainability.
We remain committed to advancing the adoption of value-based healthcare, and we look forward to continuing these vital discussions on how to enhance both clinical outcomes and cost efficiencies in the future.